NORMAL MAN. Tidd, 1978). These metabolites included xanthanoic. acid, hydroxyxanthanoic acid, hydroxypropantheline,
|
|
- Tabitha Cora Marshall
- 5 years ago
- Views:
Transcription
1 Br. J. clin. Pharmac. (1979), 7, PHARMACOKINETICS OF PROPANTHELINE BROMIDE IN NORMAL MAN C.W. VOSE, G.C. FORD, S.J.W. GRIGSON, N.J. HASKINS, M. PROUT, P.M. STEVENS, D.A. ROSE & R.F. PALMER Department of Metabolic Studies, G.D. Searle and Co. Ltd, Land End Road, High Wycombe, Bucks HP12 4HL H. RUDEL Asociacion de Investigacion, Farmacologica Mexicana A.C., Medellin No. 273, Mexico 7 DF I Six normal men were administered propantheline bromide (15 mg) in single doses intravenously, and as an oral solution in a balanced random crossover study. 2 Plasma concentrations and urinary excretion of the drug were measured after each treatment, using a stable isotope dilution assay. 3 Initial plasma concentrations of propantheline bromide ranged from 494 to 131 ng ml-' 3 min after the intravenous dose. Plasma levels of the drug decreased rapidly to reach concentrations of 4.5 to 27.2 ng ml-' 4 h after dosage. A total of 17.3% (range 8.73 to 23.69%) of the intravenous propantheline bromide was eliminated by excretion in urine. 4 Pharmacokinetic analysis of these data indicated mean biological half-lives of 3.2 min (range 1.2 to 4.2 min; distribution phase) 57.9 min (range 12.6 to 16.2 min; fast elimination phase) and 2.93 h (range 2.16 to 3.69 h; slow elimination phase). 5 Total plasma clearance was calculated as h-' (range 28.1 to h-1) and the renal clearance was h-' (range 6.7 to h-') demonstrating the importance of extra-renal routes in the elimination of propantheline bromide. 6 Following the oral dose of propantheline bromide plasma concentrations of the drug were at or below the precision level of the assay (5 ng ml-') at all times after dosage. A total of 1.8% (range.33 to 2.5%) of the propantheline bromide administered was excreted in urine. 7 The results of this study show that propantheline bromide was rapidly distributed and eliminated in man, and that extra-renal routes (probably metabolism) were the major pathways of elimination. Comparison of the data obtained following oral and intravenous administration indicate a low systemic availability of orally administered propantheline bromide. This may reflect the importance of the extra-renal routes of elimination in a 'first-pass' effect for the drug. Introduction Propantheline bromide [Figure la, (2-hydroxyethyl) di-isopropylmethylammonium bromide xanthene-9- carboxylatel is a quaternary ammonium compound possessing anticholinergic properties, used for some years in the treatment of peptic ulcer and renal colic. This compound appears to undergo appreciable metabolism in man, even after intravenous administration (Beermann, Hellstrom & Rosen, 1972). Following oral administration of "4C-labelled propantheline bromide to normal men some 7% of the administered radioactivity was excreted in urine, but the majority of this was present as metabolites of the drug (Beermann et al., 1972; Vose, Prout, Haskins, Ford, Palmer & Tidd, 1978). These metabolites included xanthanoic acid, hydroxyxanthanoic acid, hydroxypropantheline, and a number of conjugates. While the metabolism of this drug has been studied, little is known about its pharmacokinetics. This reflects the difficulty in quantifying propantheline bromide in biological fluids. A spectrophotometric method (Pfeffer, Schar, Bolton & Jacobsen, 1968) and a fluorimetric method (Westerlund & Karset, 197), utilizing ion pair extraction techniques, have been reported. However, these did not have the necessary sensitivity to measure low concentrations of propantheline bromide. Recently a more sensitive and specific assay for
2 9 C.W. VOSE ETAL. CH (CH3 )2.1I COCH2 CH2N-C4(CH3 )2 a R=-CH3 b R=CD3 Figure 1 Chemical-structures of (a) propantheline bromide and (b) deuterium labelled propantheline bromide. - propantheline bromide in. urine and plasma has been developed in these laboratories -(Ford, Guigson, -Haskins, Palmer, Prout & Vose,. 1977). This allows the compound.to be accurately.quantified in these biological fluids, with a quantitation. limit of about 5 ng ml-'. This assay uses the deuterium labelled compound (Figure lb) as te.i.trnal stadard, and multiple ion monitoring to --measure propantheline bromide in biological fluids by gas chromatography-mass spectrometry. Br The present report.describes the application of this sensitive assay to a study ofthe-plasma concentrations and urinary -.excretion of propantheline bromide in normal} man following single intravenous and oral doses of the compound, and provides some pharmacokinetic data not previously available for this compound. Methods Propanthlfine bromide was obtained from Searle de Mexico, S.A. de C.V., Mexico City. The intravenous dosage was prepared by dissolving propantheline bromide (15-.mg) in sterile.9% saline (5 ml), and the oral -solution was prepared by dissolving the drug (15 mg) in distilled water (15 ml), immediately prior to dosage. Clinical procedure The subjects weresix-..normal men aged years who had given informed consent tq participate in the study, and were judged healthy by a medical and Table 1 P-Plasrs conce*etions (ng mf-1) of propantheline brqmide following a sinle intravenourdose Time (min) Subject R{;.JZ VP V) JG RH Mean *28 J : #3 * & ; , Q : 27.2 * * * to 1. 6, TabI2 Half-i and cwarancofintravenoupropanthelinebroaodde Su*ct RG Jz VP VD JG FRH Mean T.{ (min) '3.6 :3.2 Tjb-(Mln) t :9 qt- c(hj ' a'distributiowtphase; b'fet' enrninetin phase; c 'SloW elimination pbase Plasma cleauce 1 h-1) Total Renal & *
3 PROPANTHELINE BROMIDE PHARMACOKINETICS 91 biochemical pre-trial screen. The subjects fasted and abstained from all liquids for 1 h prior to dosage, except for the ingestion of 2 ml water 1 h before dosage. The subjects were forbidden alcohol from 24 h before dosing until sample collection was completed for each experiment, and all forms of medication were forbidden from 2 weeks before the study until its completion. A 1 week wash-out interval was allowed between each pha-se of the study. On the morning of dosing each volunteer received propantheline bromide (15 mg), intravenously, or as an oral solution in water (15 ml) in a balanced random crossover. The intravenous administration of the drug was carried out at a constant rate over 2.5 min. Urine samples were collected for 12 h before dosage and during -2, 2-4, 4-6, 6-8, 8-12, 12-24, 24-48, and h after dosage, into vessels containing 1 M perchioric acid (1 ml), and stored frozen at -2C. Blood samples (1 ml) were obtained from an antecubital vein immediately before dosage, and at 3*, 5* (* these samples were taken only after the intravenous dose), 1, 15, 3 and 6 min, and 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24,27, 3,48, 72 and 96 h after dosage. Each blood sample was immediately transferred to a heparinised tube, acidified, centrifuged, and the separated plasma was added to anequal volume of.1 M perchloric acid and frozen at - 2C within one hour of collection. Extraction and analysis ofpropantheline bromide in plasma and urine An aliquot of each urine sample (1 ml) and each acidified plasma sample (5 ml, equivalent to 2.5 ml of plasma) was extracted and analyzed by the method described previously (Ford et al, 1977). Table 3 Mean cumulative urinary excretion of propantheline bromide in 48 h following intravenous and oral administration of the drug Subject RG Jz VP VD JG Rt Mean % dose of propanthetne bromide excreted as intact drug Intravenoua Oral * Urine collections wer obtained only up to 12 h after dosage, this value not included in calcuating mean value Pharmacokinetic analysis of the plasma concentration and urinary excretion data was made using Metzler's NONLIN programme. Results In all six subjects propantheline bromide was rapidly cleared from plasma after intravenous administration (Table 1). The mean concentration decreased rapidly from ng ml-l (range ng ml-') at 3 min after dosage, to 95 ngml-l (range ngml-') 3min after the i.v. dose. Thereafter the plasma levels of propantheline bromide decreased more slowly to 1.6 ng ml-' (range to 27.2 ng ml-') at 4 h after administration. At all subsequent sampling times plasma concentrations of the drug were below the level of accurate quantitation (5 ng ml-'). In four of the subjects the plasma levels of propantheline bromide exhibited a biphasic decline, whereas in the other two subjects a third phase could be resolved. The half-lives of these phases are listed in Table 2 with other pharmacokinetic parameters. The initial (distribution) phase had a half-life of 3.2 min (range min) and the second ('fast' elimination) phase had a half-life of 57.9 mm (range min). The third ('slow' elimination) phase observed for subjects VP and VD had a half-life of 2.16 and 3.69 respectively. Following the oral dose of propantheline bromide plasma levels were very low, at or below the precision level of the assay (5 ng ml-') at all times after administration, and could not be accurately measured. The cumulative urinary excretion data listed in Table 3 showed that 17.3% (range %) of the intravenous propantheline bromide was excreted in urine. However, only 1.8% (range %) of the oral dose was eliminated by this route. The majority of the urinary excretion occurred in the first 8 h regardless of the route of administration. From the plasma concentrations and the urinary excretion data the plasma clearances of intravenous propantheline bromide were calculated (Tabe 2). There was a large inter-individual variation in the total plasma clearance, which ranged from kh-i in subject VD to ' in subject 1G. In contms there was a much smaller inter-individual variation in the plasma renal clearance from 6.7 to h-l. During the study subjective observations of pharmacological effects of propantheline -bromide were reported by the subjects. Thus, following the oral dose they reported a deecree in salvary secretion, reflected by a dry mouth. This effect qieared between 3 and 6Gmi after dosage and lasted for a furthr I to 3 h. Following the intravenous doae this dry mouth sensation developed more rapidly, in some cases within a few minutes, and was ofhigher intensity and longer daration. In addition uriary hesitancy was
4 92 C.W. VOSE ETAL. observed tbolowimg the i.v. dose, and was reflected by the absence of urine samples for the first 3 or 4 collection periods in some of the volunteers. Discussion The rapid disappearance of intravenously administered propantheline bromide from plasma demonstrates a fast distribution and elimination of this drug in man. The half-lives of the phases associated with the decline in the plasma concentration of propantheline bromide are similar to those reported for a number of other quaternary ammonium compounds (Calvey, Williams, Muir & Barber, 1976; Scoular, Monks, Burgess & Turner, 1977). The very low plasma concentrations of propantheline bromide achieved after oral administration precluded their accurate measurement, and so no estimate of the rate of absorption could be obtained. This plasma level data, and the low urinary excretion of the orally administered drug indicated a low systemic availability, about 6.2% based on the mean cumulative urinary excretion data. This may account for the observed therapeutic ratio of the drug when given orally and parenterally (Moller & Rosen, 1968). Low plasma levels of orally administered propantheline bromide have been reported previously by Westerlund & Karset (197), who found plasma levels of the drug were below 4 ng ml-" (the precision level of their assay) at all times after a 3 mg oral dose. The urinary excretiot of propantheline bromide observed in the present study following its intravenous and oral administration are similar to those reported by Beermann et al. (1972) in a study of a radiolabelled form of the compound. The mean plasma clearance data collected in the present study demonstrates a high total plasma clearance of propantheline bromide, h-' (range h-1). However, the renal clearance of the drug was low, h-1 (range h-1). Thus, urinary excretion is a minor route of elimination for propantheline bromide in man, the major routes of elimination being extra-renal. Since propantheline bromide is known to be appreciably metabolized after intravenous administration (Beermann et al., 1972) this high extra-renal clearance probably reflects the importance of metabolism in the elimination of the drug. The inter-individual variation in the plasma renal clearance was low whereas the variation in total clearance was large. This suggests that the major source of inter-individual variation in the pharmacokinetics and pharmacology of propantheline bromide is the inter-individual difference in the extra-renal clearance of the drug. The apparently low systemic availability of orally administered drug observed in the present study has been reported previously (Beermann et al., 1972) from studies using carbon-14 labelled propantheline bromide. These workers suggested that this low availability reflected the enzymatic hydrolysis of the drug in the gastro-intestinal lumen and the poor absorption of quaternary ammonium compounds (Levine & Pelikan, 1964). However, the present study indicates that extra-renal routes, probably metabolism as discussed above, are the major pathways of elimination of propantheline bromide. Thus the low systemic availability of this compound may also result from a 'first pass' metabolism of the absorbed drug following oral administration. Although the present study indicates a low availability of oral propantheline bromide there is good evidence of its pharmacological activity in man (Moller & Rosen, 1968; Gibaldi & Grundhofer, 1975). These workers demonstrated a dose related suppression of salivary secretion with increasing oral doses of propantheline bromide. Since for most anticholinergics suppression of salivary secretion reflects the suppression of gastric secretion (Ivey, 1975) these studies provide evidence of the effectiveness of orally administered propantheline bromide. Further evidence of the pharmacological activity of this drug after oral administration was provided in the present study by the subjective observation of anticholinergic side effects in men having very low plasma levels of propantheline bromide. The pharmacokinetic data described in the present report may be of value in further studies on propantheline bromide and in studies of the relationship between blood levels and pharmacological activity. References BEERMANN, B., HELLSTROM, K. & ROSEN, A. (1972). On. the metabolism of propantheline in man. Clin. Pharmac. Ther., 13, CALVEY, T.N., WILLIAMS, N.E., MUIR, K.T. & BARBER, H.E. (1976). Plasma concentration of edrophonium in man. Clin. Pharmac. Ther., 19, FORD, G.C., GRIGSON, SJ.W., HASKINS, NJ., PALMER, R.F., PROUT, M. & VOSE, C.W. (1977). Measurement of propantheline ion in biological fluids after administering propantheline bromide to man. Biomed. Mass Spectrom., 4, GIBALDI, M. & GRUNDHOFER, B. (1975). Biopharmaceutic influences on the anticholinergic effects of propantheline. Clin. Pharmac. Ther., 18, IVEY, K. (1975). Anticholinergics: Do they work? Gastroenterology, 68, LEVINE, R.R. & PELIKAN, E.A. (1964). Mechanisms of drug absorption and excretion. Ann. Rev. Pharmac., 4,
5 PROPANTHELINE BROMIDE PHARMACOKINETICS 93 MOLLER, J. & ROSEN, A. (1968). Comparative studies on intramuscular and oral effective doses of some anticholinergic drugs. Acta Med. Scand., 184, PFEFFER, M., SCHAR, J.M., BOLTON, S. & JACOBSEN, R. (1968). Human urinary excretion of quaternary ammonium compounds anisotropinemethyl bromide and propantheline bromide. J. pharm. Sci., 57, SCOULAR, I.T., MONKS, A., BURGESS, C. & TURNER, P. (1977). Human studies of the bioavailability of a quaternary ammonium compound, tiemonium bromide and tiemonium methosulphate. Curr. med. Res. Opin., 4, VOSE, C.W., PROUT, M., HASKINS, NJ., FORD, G.C., PALMER, R.F. & TIDD, MJ. (1978). Identification of some urinary metabolites of propantheline bromide. Xenobiotica (in press). WESTERLUND, D. & KARSET, K.H. (197). Fluorimetric determination of propantheline in human blood plasma by an ion pair extraction method. Acta Pharin. Suecica., 7, (Received December 21, 1977)
Preliminary studies of the pharmacokinetics and pharmacodynamics
Br. J. clin. Pharmac. (1987), 23, 137-142 Preliminary studies of the pharmacokinetics and pharmacodynamics of prochlorperazine in healthy volunteers WENDY B. TAYLOR & D. N. BATEMAN Wolfson Unit of Clinical
More informationUsing Accelerator Mass Spectrometry to Explain the Pharmacokinetics of Vismodegib Cornelis E.C.A. Hop
Using Accelerator Mass Spectrometry to Explain the Pharmacokinetics of Vismodegib Cornelis E.C.A. Hop Topics to be Addressed Why AMS? AMS for mass balance studies with vismodegib AMS for absolute bioavailability
More informationThe pharmacokinetics of nedocromil sodium, a new drug for the treatment of reversible obstructive airways disease, in.
Br. J. clin. Pharmac. (1987), 24, 493-501 The pharmacokinetics of nedocromil sodium, a new drug for the treatment of reversible obstructive airways disease, in human volunteers and patients with reversible
More informationFlecainide pharmacokinetics in healthy volunteers: the influence of urinary ph
Br. J. clin. Pharmac. (1985), 20, 333-338 Flecainide pharmacokinetics in healthy volunteers: the influence of urinary ph A. JOHNSTON, S. WARRNGTON' & P. TURNER Department of Clinical Pharmacology, St Bartholomew's
More informationThe dependence of paracetamol absorption on the rate of gastric emptying
Br. J. Pharmac. (1973), 47, 415-421. The dependence of paracetamol absorption on the rate of gastric emptying R.. HADING, J. NIMMO, L F. PRSOTT AND P. TOTHILL University Departments of Therapeutics and
More informationPharmacokinetics of ibuprofen in man. I. Free and total
Pharmacokinetics of ibuprofen in man. I. Free and total area/dose relationships Ibuprofen kinetics were studied in 15 subjects after four oral doses. Plasma levels of both total and free ibuprofen were
More informationMAN. likely to be useful in the management of patients. on long term treatment and may provide a suitable
Br. J. clin. Pharmac. (1975) 2, 327-332 PREDNISOLONE LEVELS IN THE PLASMA AND URINE: A STUDY OF TWO PREPARATIONS IN JUDITH ENGLISH, J. CHAKRABORTY & V. MARKS Department of Biochemistry, University of Surrey,
More informationOsnove farmakokinetike. Aleš Mrhar. Prirejeno po. A First Course in Pharmacokinetics and Biopharmaceutics by David Bourne,
Osnove farmakokinetike Aleš Mrhar Prirejeno po A First Course in Pharmacokinetics and Biopharmaceutics by David Bourne, College of Pharmacy, University of Oklahoma Pharmacokinetics/Pharmacodynamics Pharmacodynamics
More informationIII. TOXICOKINETICS. Studies relevant to the toxicokinetics of inorganic chloramines are severely
III. TOXICOKINETICS Introduction Studies relevant to the toxicokinetics of inorganic chloramines are severely limited. However, studies done with various chlorinated amino compounds (including organic
More informationThe pharmacokinetics and dose proportionality of cilazapril
Br. J. clin. Pharmac. (1989), 27, 199S-204S The pharmacokinetics and dose proportionality of cilazapril J. MASSARELLA, T. DEFEO, A. LIN, R. LIMJUCO & A. BROWN Departments of Drug Metabolism and Clinical
More informationIntrasubject Variation in Elimination Half-Lives of Drugs Which Are Appreciably Metabolized
Journal of Pharmacokinetics and Biopharrnaceutics, Vol. 1, No. 2, 1973 SCIENTIFIC COMMENTARY Intrasubject Variation in Elimination Half-Lives of Drugs Which Are Appreciably Metabolized John G. Wagner 1
More informationDisposition of metronidazole and its effects on sulphasalazine
Br. J. clin. Pharmac. (1986), 21, 431-435 Disposition of metronidazole and its effects on sulphasalazine metabolism in patients with inflammatory bowel disease J. L. SHAFFER*,' A. KERSHAW2 & J. B. HOUSTON2
More informationPharmacokinetic and pharmacodynamic interactions between phenprocoumon and atenolol or metoprolol
Br. J. clin. Pharmac. (1984), 17, 97S-12S Pharmacokinetic and pharmacodynamic interactions between phenprocoumon and atenolol or metoprolol H. SPAHN', W. KIRCH2,. MUTSCHLR',.. OHNHAUS2, N. R. KITFRINGHAM2,
More informationSection 5.2: Pharmacokinetic properties
Section 5.2: Pharmacokinetic properties SmPC training presentation Note: for full information refer to the European Commission s Guideline on summary of product characteristics (SmPC) SmPC Advisory Group
More informationPHA 5127 FINAL EXAM FALL On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 5127 FINAL EXAM FALL 1997 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Question Points 1. /14 pts 2. /10 pts 3. /8 pts 4 /8 pts 5. /12 pts 6. /8 pts
More informationPrinciples of Drug Action. Intro to Pharmacology: Principles of Courework Drug Action Intro to Pharmacology
Principles of Drug Action Intro to Pharmacology: Principles of Courework 102.3 Drug Action Intro to Pharmacology Directions Read the PPT and complete R.E.A.D. Assignment. There are videos embedded within
More informationHuman ADME Study Design Considerations in Healthy Subjects and in Patients
Human ADME Study Design Considerations in Healthy Subjects and in Patients Daria Stypinski BSc (Pharm), PhD Clinical Pharmacology Sciences Nov 18, 2015 Learning Goals and Outline What is a human ADME study?
More informationBasic Biopharmaceutics, Pharmacokinetics, and Pharmacodynamics
Basic Biopharmaceutics, Pharmacokinetics, and Pharmacodynamics Learning Outcomes Define biopharmaceutics Describe 4 processes of pharmacokinetics Describe factors that affect medication absorption Describe
More informationPharmaceutics I صيدالنيات 1. Unit 2 Route of Drug Administration
Pharmaceutics I صيدالنيات 1 Unit 2 Route of Drug Administration 1 Routs of Drug administration The possible routes of drug entry into the body may be divided into two classes: Parenteral Rout Enteral Rout
More informationDr. M.Mothilal Assistant professor
Dr. M.Mothilal Assistant professor Bioavailability is a measurement of the rate and extent of drug that reaches the systemic circulation from a drug product or a dosage form. There are two different types
More informationGastrointestinal side effects after intravenous erythromycin
Br. J. clin. Pharmac. (1986), 21, 295-299 Gastrointestinal side effects after intravenous erythromycin lactobionate K. M. DOWNEY & D. M. CHAPUT DE SAINTONGE Department of Pharmacology and Therapeutics,
More information2- Minimum toxic concentration (MTC): The drug concentration needed to just produce a toxic effect.
BIOPHARMACEUTICS Drug Product Performance Parameters: 1- Minimum effective concentration (MEC): The minimum concentration of drug needed at the receptors to produce the desired pharmacologic effect. 2-
More informationPharmacokinetics in the critically ill. Intensive Care Training Program Radboud University Medical Centre Nijmegen
Pharmacokinetics in the critically ill Intensive Care Training Program Radboud University Medical Centre Nijmegen In general... Critically ill patients are at higher risk for ADE s and more severe ADE
More informationBASIC PHARMACOKINETICS
BASIC PHARMACOKINETICS MOHSEN A. HEDAYA CRC Press Taylor & Francis Croup Boca Raton London New York CRC Press is an imprint of the Taylor & Francis Group, an informa business Table of Contents Chapter
More informationline sulphate in freon propellant forming a 5 Mm particle diameter. A nalytical procedures Heparinized blood samples were immediately
Br. J. Pharmac. (1974), 50, 587-591 METABOLISM OF ISOPRENALINE AFTER AEROSOL AND DIRECT INTRABRONCHIAL ADMINISTRATION IN MAN AND DOG E.W. BLACKWELL, R.H. BRIANT, M.E. CONOLLY, D.S. DAVIES & C.T. DOLLERY
More informationRoutes of drug administration
Routes of drug administration Definition:- A route of administration in pharmacy is the path by which a drug is taken into the body. Classification:- The various routes of administrations are classified
More informationInternational Journal of Pharma and Bio Sciences
International Journal of Pharma and Bio Sciences RESEARCH ARTICLE BIOPHARMACEUTICS USE OF SIMPLE SPECTROPHOTOMETRIC METHOD FOR ESTIMATION OF THEOPHYLLINE (TH) IN SALIVA AND URINE OF HEALTHY HUMAN VOLUNTEER
More informationPHARMACOKINETIC STUDY OF DEXTROMETHORPHAN WITH URINARY EXCRETION
PHARMACOKINETIC STUDY OF DEXTROMETHORPHAN WITH URINARY EXCRETION Heesun CHUNG, Wonkyung YANG, Hwakyung CHOI, Wontack JIN, Sihnyoung SIHN, Youngchan YOO National Institute of Scientific Investigation, Seoul,
More informationAutonomic Pharmacology: Cholinergic agonists
Autonomic Pharmacology: Cholinergic agonists Öner Süzer www.onersuzer.com osuzer@istanbul.edu.tr Last update: 23.01.2013 1 Acetylcholine Acetylcholine (ACh), the naturally occurring neurotransmitter for
More informationA novel microdose approach to assess bioavailability, intestinal absorption, gut metabolism, and hepatic clearance of simeprevir in healthy volunteers
A novel microdose approach to assess bioavailability, intestinal absorption, gut metabolism, and hepatic clearance of simeprevir in healthy volunteers Sivi Ouwerkerk-Mahadevan, 1 Jan Snoeys, 1 Alex Simion,
More informationDefine the terms biopharmaceutics and bioavailability.
Pharmaceutics Reading Notes Define the terms biopharmaceutics and bioavailability. Biopharmaceutics: the area of study concerning the relationship between the physical, chemical, and biological sciences
More informationLack of pharmacokinetic interaction between the oral anti-influenza neuraminidase inhibitor prodrug oseltamivir and antacids
Blackwell Science, Ltdxford, UKBJCPBritish Journal of Clinical Pharmacology0306-5251Blackwell Science, 200254riginal Articleseltamivir and antacids lack of kinetic interactionp. Snell et al. Lack of pharmacokinetic
More informationGeneral Principles of Pharmacology and Toxicology
General Principles of Pharmacology and Toxicology Parisa Gazerani, Pharm D, PhD Assistant Professor Center for Sensory-Motor Interaction (SMI) Department of Health Science and Technology Aalborg University
More informationBIOPHARMACEUTICS and CLINICAL PHARMACY
11 years papers covered BIOPHARMACEUTICS and CLINICAL PHARMACY IV B.Pharm II Semester, Andhra University Topics: Absorption Distribution Protein binding Metabolism Excretion Bioavailability Drug Interactions
More informationPRODUCT INFORMATION. Ammonium chloride is an expectorant that has an irritant effect on mucous membranes.
PRODUCT INFORMATION BENADRYL Original Oral Liquid (New Formula) Name of the Medicine Diphenhydramine hydrochloride Ammonium chloride The chemical name for diphenhydramine hydrochloride is 2-(diphenylmethoxy)-N,Ndimethylethanamine
More informationLatest Press Release. pink roulette where the boys come out and play
corp@stantec.com Latest Press Release pink roulette where the boys come out and play S Oxycodone is a strong narcotic pain-reliever and cough suppressant similar to morphine, codeine, and hydrocodone.
More information3/31/2009. Phase 0 Microdosing Studies with Renin Inhibitors. Disclaimer. Overview of Today s Presentation. J. Chris Jensen Consultant
Phase 0 Microdosing Studies with Renin Inhibitors J. Chris Jensen Consultant Speedel Holding Ltd. Basel, Switzerland Disclaimer The views and opinions expressed in the following PowerPoint slides are those
More informationSaliva Versus Plasma Bioequivalence of Rusovastatin in Humans: Validation of Class III Drugs of the Salivary Excretion Classification System
Drugs R D (2015) 15:79 83 DOI 10.1007/s40268-015-0080-1 ORIGINAL RESEARCH ARTICLE Saliva Versus Plasma Bioequivalence of Rusovastatin in Humans: Validation of Class III Drugs of the Salivary Excretion
More informationRelative potency of prorenoate potassium and spironolactone in
Br. J. clin. Pharmac. (1984), 18, 169-174 Relative potency of prorenoate potassium and spironolactone in attenuating diuretic induced hypokalaemia G. T. McINNES*, I. R. HARRISON, J. R. SHELTON, R. M. PERKINS
More informationIdentifying New Cannabis Use with Urine Creatinine- Normalized THCCOOH Concentrations and Time Intervals Between Specimen Collections *
Identifying New Cannabis Use with Urine Creatinine- Normalized THCCOOH Concentrations and Time Intervals Between Specimen Collections * Michael L. Smith 1, Allan J. Barnes 2, and Marilyn A. Huestis 2,
More informationDrug Dosing in Renal Insufficiency. Coralie Therese D. Dimacali, MD College of Medicine University of the Philippines Manila
Drug Dosing in Renal Insufficiency Coralie Therese D. Dimacali, MD College of Medicine University of the Philippines Manila Declaration of Conflict of Interest For today s lecture on Drug Dosing in Renal
More informationGastric, intestinal and colonic absorption of metoprolol in
Br. J. clin. Pharmac. (1985), 19, 85S-89S Gastric, intestinal and colonic absorption of metoprolol in the rat J. DOMENECH', M. ALBA', J. M. MORERA', R. OBACH' & J. M. PLA DELFINA2 'Department of Pharmaceutics,
More informationpreliminaryfinding. Current theories of iron metabolism would explain dispute over urinary iron, which is agreed by all to be very small and
148 J. Physiol. (I938) 94, I48-I54 6I5.739.I3:6I2.386 THE ABSORPTION AND EXCRETION OF IRON FOLLOWING ORAL AND INTRAVENOUS ADMINISTRATION BY R. A. McCANCE AND E. M. WIDDOWSON From the Biochemical Laboratory,
More informationSansom & Manston, 1963) and rats (Payne & Sansom, 1963). It appeared
J. Physiol. (1964), 170, pp. 613-620 613 Printed in Great Britain THE RELATIVE TOXICITY IN RATS OF DISODIUM ETHYLENE DIAMINE TETRA-ACETATE, SODIUM OXALATE AND SODIUM CITRATE BY J. M. PAYNE AND B. F. SANSOM
More informationPHARMACOKINETICS OF DRUG ABSORPTION
Print Close Window Note: Large images and tables on this page may necessitate printing in landscape mode. Applied Biopharmaceutics & Pharmacokinetics > Chapter 7. Pharmacokinetics of Oral Absorption >
More informationPharmacokinetics I. Dr. M.Mothilal Assistant professor
Pharmacokinetics I Dr. M.Mothilal Assistant professor DRUG TRANSPORT For a drug to produce a therapeutic effect, it must reach to its target and it must accumulate at that site to reach to the minimum
More informationPHA First Exam Fall 2013
PHA 5127 First Exam Fall 2013 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Question Set/Points I. 30 pts II. III. IV 20 pts 20 pts 15 pts V. 25 pts VI.
More informationWHY... 8/21/2013 LEARNING OUTCOMES PHARMACOKINETICS I. A Absorption. D Distribution DEFINITION ADME AND THERAPEUIC ACTION
PHARMACOKINETICS I Absorption & Distribution LEARNING OUTCOMES By the end of the lecture students will be able to.. Dr Ruwan Parakramawansha MBBS, MD, MRCP(UK),MRCPE, DMT(UK) (2013/08/21) Define pharmacokinetics,
More informationD9G : Oro-Mucosal Dosage Forms Development Background Paper
D9G : Oro-Mucosal Dosage Forms Development Background Paper Introduction This background paper is intended to provide a basic rationale for initial formulation efforts, and define some of the terminology
More informationStudy of the bioavailability of pindolol in malabsorption
Br. J. clin. Pharmac. (1984), 18, 632-637 Study of the bioavailability of pindolol in malabsorption syndromes D. EVARD1, J-P. AUBRY2, Y. LE QUINTREC1, G. CHEYMOL2, & A. CHEYMOL2 'Service de Gastro-ent6rologie,
More informationEFFECT OF CARBENOXOLONE ON THE GASTRIC MUCOSAL BARRIER IN MAN AFTER ADMINISTRATION OF TAUROCHOLIC ACID
GASTROENTEROLOGY 64: 1101-1105, 1973 Copyright 1973 by The Williams & Wilkins Co. Vol. 64 No.6 Printed in U.S.A. EFFECT OF CARBENOXOLONE ON THE GASTRIC MUCOSAL BARRIER IN MAN AFTER ADMINISTRATION OF TAUROCHOLIC
More informationIn vitro and in vivo deconvolution assessment of drug release kinetics from oxprenolol Oros preparations
Br. J. clin. Pharmac. (1985), 19, 151S-162S In vitro and in vivo deconvolution assessment of drug release kinetics from oxprenolol Oros preparations F. LANGENBUCHER & J. MYSICKA Pharmaceutical Development,
More informationIntroduction to. Pharmacokinetics. University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D
Introduction to 1 Pharmacokinetics University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D 2 Learning objectives Understand compartment models and how they effects
More informationPassage of paracetamol into breast milk and its subsequent metabolism by the neonate
Br. J. clin. Pharmac. (1987), 24, 63-67 Passage of paracetamol into breast milk and its subsequent metabolism by the neonate L. J. NOTARIANNI1, H. G. OLDHAM2 & P. N. BNNTT' 'School of Pharmacy and Pharmacology,
More informationDOMPERIDONE BNF 4.6. Domperidone is a dopamine type 2-receptor antagonist. It is structurally related to the
DOMPERIDONE BNF 4.6 Class: Prokinetic anti-emetic. Indications: Nausea and vomiting, dysmotility dyspepsia, gastro-oesophageal reflux. Pharmacology Domperidone is a dopamine type 2-receptor antagonist.
More informationClick to edit Master title style
A Short Course in Pharmacokinetics Chris Town Research Pharmacokinetics Outline Pharmacokinetics - Definition Ideal Pharmacokinetic Parameters of a New Drug How do we optimize PK for new compounds Why
More informationUNIVERSITY OF THE WEST INDIES, ST AUGUSTINE
UNIVERSITY OF THE WEST INDIES, ST AUGUSTINE FACULTY OF MEDICAL SCIENCES SCHOOL OF PHARMACY BACHELOR OF SCIENCE IN PHARMACY DEGREE COURSE SYLLABUS COURSE TITLE: COURSE CODE: BIOPHARMACEUTICS, NEW DRUG DELIVERY
More informationPharmacokinetics of intravenous and oral salbutamol and its sulphate conjugate
Br. J. clin. Pharmac. (1986), 22, 587-593 Pharmacokinetics of intravenous and oral salbutamol and its sulphate conjugate D. J. MORGAN1, J. D. PAULL2, BARBARA H. RICHMOND1, ELISABETH WILSON-EVERED2 & S.
More informationIPRAVENT Respules/Respirator solution (Ipratropium bromide)
Published on: 19 Sep 2014 IPRAVENT Respules/Respirator solution (Ipratropium bromide) Composition IPRAVENT Respules Each 2 ml contains: Ipratropium Bromide BP equivalent to Ipratropium Bromide (anhydrous)
More informationanticholinergic compounds
Gut, 1968, 9, 590-596 Clinical evaluation of three long-acting anticholinergic compounds MICHAEL D. KAYE, JOHN RHODES, AND PETER M. SWEETNAM From the Cardiff Royal Infirmary Anticholinergic drugs are used
More informationThe usual dose is 40 mg daily with amoxycillin 1.5 g (750 mg b.d.) for 2 weeks. Up to 2 g/day of amoxycillin has been used in clinical trials.
Name Gasec - 2 Gastrocaps Composition Gasec-20 Gastrocaps Each Gastrocaps contains: Omeprazole 20 mg (in the form of enteric-coated pellets) Properties, effects Proton Pump Inhibitor Omeprazole belongs
More informationBasic Concepts of TDM
TDM Lecture 1 5 th stage What is TDM? Basic Concepts of TDM Therapeutic drug monitoring (TDM) is a branch of clinical pharmacology that specializes in the measurement of medication concentrations in blood.
More informationPharmacokinetics Overview
Pharmacokinetics Overview Disclaimer: This handout and the associated lectures are intended as a very superficial overview of pharmacokinetics. Summary of Important Terms and Concepts - Absorption, peak
More informationTDM. Measurement techniques used to determine cyclosporine level include:
TDM Lecture 15: Cyclosporine. Cyclosporine is a cyclic polypeptide medication with immunosuppressant effect. It has the ability to block the production of interleukin-2 and other cytokines by T-lymphocytes.
More informationRanitidine-a new H2-receptor antagonist
Ranitidine-a new H2-receptor antagonist Gut, 1980, 21, 187-191 P WOODINGS, G T DIXON, C HARRISON, P CARY, AND D A RICHARDS Glaxo Group Research Ltd, Ware, Herts SUMMARY The pharmacokinetics and gastric
More informationEuropean public MRL assessment report (EPMAR)
15 November 2016 EMA/CVMP/351687/2016 Committee for Medicinal Products for Veterinary Use European public MRL assessment report (EPMAR) (bovine species) On 17 October 2016 the European Commission adopted
More informationImpairment of cognitive function associated with hydroxyamylobarbitone accumulation in patients with renal insufficiency
Br. J. Pharmac. (1972), 45, 36-367. Impairment of cognitive function associated with hydroxyamylobarbitone accumulation in patients with renal insufficiency K. BALASUBRAANIA, G. E. AWER, J. E. F POHL.
More informationGlycopyrronium Bromide and Neostigmine Metilsulfate 0.5mg/2.5mg per ml
New Zealand Datasheet Glycopyrronium Bromide and Neostigmine Metilsulfate 0.5mg/2.5mg per ml Solution for injection Glycopyrronium bromide 0.5 mg/ml & Neostigmine metilsulfate 2.5 mg/ml Presentation is
More informationDRUG ELIMINATION II BILIARY EXCRETION MAMMARY, SALIVARY AND PULMONARY EXCRETION
DRUG ELIMINATION II BILIARY EXCRETION MAMMARY, SALIVARY AND PULMONARY EXCRETION ROUTE OF DRUG ADMINISTRATION AND EXTRAHEPATIC DRUG METABOLISM The decline in plasma concentration after drug administration
More informationEnteral and parenteral nutrition in GI failure and short bowel syndrome
Enteral and parenteral nutrition in GI failure and short bowel syndrome Alastair Forbes University College London Intestinal failure Inadequate functional intestine to allow health to be maintained by
More informationPharmacokinetics: The Basics
Pharmacokinetics: The Basics 2017 Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, MD January 2017 MRC2.CORP.D.00200 1 advice or professional diagnosis. Users seeking medical advice
More informationDetermination of bioavailability
Pharmaceutics 2 Bioavailability Bioavailability is the rate and extent to which an administered drug reaches the systemic circulation. For example, if 100 mg of a drug is administered orally and 70 mg
More informationExcretion of Drugs. Prof. Hanan Hagar Pharmacology Unit Medical College
Excretion of Drugs Prof. Hanan Hagar Pharmacology Unit Medical College Excretion of Drugs By the end of this lecture, students should be able to! Identify main and minor routes of excretion including renal
More informationTIOVA Inhaler (Tiotropium bromide)
Published on: 18 Sep 2014 TIOVA Inhaler (Tiotropium bromide) Composition TIOVA Inhaler Each actuation delivers: Tiotropium Bromide Monohydrate IP equivalent to Tiotropium... 9 mcg Suspended in propellant
More informationDEPARTMENT OF PHARMACOLOGY AND THERAPEUTIC UNIVERSITAS SUMATERA UTARA
METABOLISME dr. Yunita Sari Pane DEPARTMENT OF PHARMACOLOGY AND THERAPEUTIC UNIVERSITAS SUMATERA UTARA Pharmacokinetic absorption distribution BIOTRANSFORMATION elimination Intravenous Administration Oral
More informationPARACOD Tablets (Paracetamol + Codeine phosphate)
Published on: 22 Sep 2014 PARACOD Tablets (Paracetamol + Codeine phosphate) Composition PARACOD Tablets Each effervescent tablet contains: Paracetamol IP...650 mg Codeine Phosphate IP... 30 mg Dosage Form/s
More informationAbsolute bioavailability and pharmacokinetic studies in early clinical development using microdose and microtracer approaches.
Absolute bioavailability and pharmacokinetic studies in early clinical development using microdose and microtracer approaches. Dr Lloyd Stevens Senior Research Fellow Pharmaceutical Profiles Nottingham,
More informationAROMASIN 25mg (Tablets)
APPROVED PACKAGE INSERT AROMASIN SCHEDULING STATUS: S4 PROPRIETARY NAME AND DOSAGE FORM: AROMASIN 25mg (Tablets) COMPOSITION: Each sugar-coated tablet contains 25 mg exemestane. Preservative: methyl p-hydroxybenzoate
More informationPharmacokinetic and absolute bioavailability studies in early clinical development using microdose and microtracer approaches.
Pharmacokinetic and absolute bioavailability studies in early clinical development using microdose and microtracer approaches. Lloyd Stevens PhD Senior Research Fellow Pharmaceutical Profiles Nottingham,
More informationMETHODS OF STUDYING BIOAVAILABILITY AND BIOEQUIVALENCE
METHODS OF STUDYING BIOAVAILABILITY AND BIOEQUIVALENCE INTRODUCTION: A multisource drug product is a drug product that contains the same active drug substance in the same dosage form and is marketed by
More informationPHA5128 Dose Optimization II Case Study I Spring 2013
Silsamicin is an investigational compound being evaluated for its antimicrobial effect. The route of administration for this drug is via intravenous bolus. Approximately 99.9% of this drug is eliminated
More informationGuideline for Bioequivalence Studies of Generic Products
English translation of Attachment 1 of Division-tification 0229. 10 of the Pharmaceutical and Food Safety Bureau, dated February 29, 2012 Guideline for Bioequivalence Studies of Generic Products Index
More informationPosology. Posology and Dosage Regimen: Factors Affecting Drug Dosage: 08/09/ ) Age: 1. Young s Rule, based on age:
Posology and Dosage Regimen: Posology Posology: (Derived from the Greek posos- how much, and logos- science) is the branch of medicine/pharmacy dealing with doses. Posology is a branch of medical science
More informationTracer studies in GSK for Discovery and Development
Tracer studies in GSK for Discovery and Development 3 rd June 2010...a ripple or a wavefront? Graeme Young, DMPK, GlaxoSmithKline R&D, Ware, UK Outline Historical use of AMS at GSK variety of ADME studies;
More informationWHY INTRAMUSCULAR METHOTREXATE MAY BE MORE EFFICACIOUS THAN ORAL DOSING IN PATIENTS WITH RHEUMATOID ARTHRITIS
British Journal of Rheumatology 1997;36:86 90 WHY INTRAMUSCULAR METHOTREXATE MAY BE MORE EFFICACIOUS THAN ORAL DOSING IN PATIENTS WITH RHEUMATOID ARTHRITIS R. A. HAMILTON and J. M. KREMER Albany College
More informationBrand and Generic Drugs. Educational Objectives. Absorption
Peter J. Rice, PharmD, PhD Associate Professor of Pharmacology East Tennessee State University Educational Objectives Pharmacokinetic Processes Distribution Metabolism Excretion Similarities Active ingredient(s)
More informationThe disposition of primidone in elderly patients
Br. J. clin. Pharmac. (1990), 30, 607-611 The disposition of primidone in elderly patients C. MARTINESl*, G. GATTIl, E. SASS02, S. CALZETIT2 & E. PERUCCA' 'Clinical Pharmacology Unit, Department of Internal
More informationA Pharmacokinetic Study to Compare Two Simultaneous 400 µg Doses with a Single 800 µg Dose of Oral Transmucosal Fentanyl Citrate
Vol. 26 No. 2 August 2003 Journal of Pain and Symptom Management 743 Original Article A Pharmacokinetic Study to Compare Two Simultaneous 400 µg Doses with a Single 800 µg Dose of Oral Transmucosal Fentanyl
More information1 - Drug preparations and route of drug administration
1 - Drug preparations and route of drug administration - There are many ways to administer drugs 1. Enteral > drugs taken into gastro-intestinal (GI) tract, e.g. swallowing a pill 2. Parenteral > drugs
More informationDEFINITIONS. Pharmacokinetics. Pharmacodynamics. The process by which a drug is absorbed, distributed, metabolized and eliminated by the body
PHARMACOLOGY BASICS DEFINITIONS Pharmacokinetics The process by which a drug is absorbed, distributed, metabolized and eliminated by the body Pharmacodynamics The interactions of a drug and the receptors
More informationIntroduction to. Pharmacokinetics. University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D
Introduction to 1 Pharmacokinetics University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D 2 Learning objectives Understand compartment models and how they effects
More informationD- Xylose Absorption Test
D- Xylose Absorption Test - Objectives a) To test the function of the upper small intestine. b) To learn the technique of D-xylose estimation - Introduction: The small intestine can be studied in two parts,the
More informationPROCAINE PENICILLIN ADMINISTERED ORALLY: COMPARISON WITH SODIUM PENICILLIN*
PROCAINE PENICILLIN ADMINISTERED ORALLY: COMPARISON WITH SODIUM PENICILLIN* WILLIAM P. BOGER, M.D. AND JOHN 0. BEATTY, M.D. There are to our knowledge, oniy two reports on the oral administration of procaine
More informationA. Definition. B. Epidemiology. C. Classification. i. Pharmacokinetic DIs. ii. Pharmacodynamic DIs. D. Recognition. E. Prevention
DRUG OUTLINE A. Definition B. Epidemiology Dr Ruwan Parakramawansha MBBS, MD, MRCP(UK),MRCPE, DMT(UK) (2013/09/05) C. Classification i. Pharmacokinetic DIs ii. Pharmacodynamic DIs D. Recognition E. Prevention
More informationEffect of Histamine H2-receptor Antagonists on. Acetaminophen and its Metabolites in Human Plasma
Jpn. J. Pharm. Health Care Sci. Effect of Histamine H2-receptor Antagonists on Acetaminophen and its Metabolites in Human Plasma Hiroki Itoh* and Masaharu Takeyama Department of Clinical Pharmacy, Oita
More informationReview article: immediate-release proton-pump inhibitor therapy potential advantages
Aliment Pharmacol Ther 25; 22 (Suppl. 3): 25 3. Review article: immediate-release proton-pump inhibitor therapy potential advantages C. W. HOWDEN Division of Gastroenterology, Northwestern University Feinberg
More informationThe excretion of zopiclone into breast milk
Br. J. clin. Pharmac. (1990), 30, 267-271 The excretion of zopiclone into breast milk I. MATHESON1, H. A. SANDE2 & J. GAILLOT3 'Department of Pharmacotherapeutics, University of Oslo, Oslo, 2Department
More information1. If the MTC is 100 ng/ml and the MEC is 0.12 ng/ml, which of the following dosing regimen(s) are in the therapeutic window?
Page 1 PHAR 750: Biopharmaceutics/Pharmacokinetics October 23, 2009 - Form 1 Name: Total 100 points Please choose the BEST answer of those provided. For numerical answers, choose none of the above if your
More informationPharmacokinetic Phase
RSPT 2217 Principles of Drug Action Part 2: The Pharmacokinetic Phase Gardenhire Chapter 2; p. 14-25 From the Text Common Pathways for Drug Box 2-3; page 18 Plasma Half-lives of Common Drugs Table 2-4;
More informationOrientation for New Child and Adolescent Psychiatry Residents: Module Four Pediatric Psychopharmacology
Orientation for New Child and Adolescent Psychiatry Residents: Module Four Pediatric Psychopharmacology Objective: To discuss basic principles of psychopharmacology in children and adolescents. Pharmacokinetics:
More information